1. Scrip
  2. >>Business
  3. >>Strategy

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Bayer cross night
• Source: Bayer

It has been a good week for Bayer’s oncology franchise, securing a third indication for its prostate cancer blockbuster Nubeqa and presenting positive data on its investigational menopause drug elinzanetant in a breast cancer study.

Key Takeaways
  • Nubeqa is now the only approved androgen receptor inhibitor for the treatment of hormone-sensitive prostate cancer, in combination with androgen deprivation therapy, with or without chemotherapy.

The US Food and Drug Administration has given the green light to Nubeqa (darolutamide) in combination with androgen deprivation therapy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart

 
• By Joseph Haas

Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data

 
• By Jessica Merrill

R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.

More from Therapy Areas

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

 
• By Jessica Merrill

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.